Form 4: Vaxcyte Director Anne S. Drapeau Acquires Shares

Vaxcyte, Inc. Director Anne S. Drapeau reported a transaction involving the acquisition of 2,265 shares of common stock and the grant of stock options for 11,389 shares.

Summary

• Director Anne S. Drapeau acquired 2,265 shares of Vaxcyte, Inc. common stock on June 15, 2026.
• The acquisition of these shares was valued at $0, indicating they were likely granted as part of compensation.
• Following this transaction, Ms. Drapeau beneficially owns 12,481 shares of common stock.
• Additionally, Ms. Drapeau was granted a stock option to purchase 11,389 shares of common stock at an exercise price of $49.56, with an expiration date of June 15, 2036.
• These options are subject to vesting conditions, with full vesting expected by June 15, 2027, or the day prior to the next annual meeting of stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports routine insider equity awards and acquisitions rather than significant financial performance or strategic shifts.

Positives

• Director acquisition of shares can signal confidence in the company's future prospects.
• Granting of stock options indicates a long-term incentive for management to align with shareholder interests.
• The vesting schedule for RSUs and stock options encourages continued service and commitment to the company.

Negatives

• The acquisition of 2,265 shares at a $0 value suggests these were likely awarded as compensation rather than purchased on the open market, which may not reflect direct investment.
• The exercise price of the stock option ($49.56) is significantly higher than the current market price, implying the option may not be immediately in-the-money.

Risks

• The vesting of restricted stock units (RSUs) and stock options is contingent upon the Reporting Person's continuous service through the vesting date, meaning departure from the company before vesting would result in forfeiture.
• The stock options have an exercise price of $49.56, which may not be achievable if the stock price does not appreciate sufficiently by the vesting or expiration dates.

Future Outlook

The future outlook for the stock options and RSUs is tied to the company's stock performance, with full vesting expected by June 15, 2027, or the day prior to the next annual meeting of stockholders, subject to continuous service.

Industry Context

StockSavvy.ai notes that insider transactions, such as those reported on Form 4, are closely watched by investors as they can provide insights into management's perception of the company's value and future prospects. The grant of stock options at a price above the current market price suggests management's belief in significant future stock appreciation.

Stakeholder Impact

• Shareholders: The acquisition of shares by a director may be viewed positively, suggesting insider confidence. However, the nature of the acquisition (likely compensation) and the strike price of options are key considerations.
• Employees: The vesting schedules for RSUs and options are standard incentives for key personnel, promoting retention and alignment with company goals.
• Management: The stock options provide a direct financial incentive for management to drive company performance and increase shareholder value.

Next Steps

• Vesting of restricted stock units and stock options according to the specified schedule.
• Potential exercise of stock options if the stock price exceeds the exercise price of $49.56.

Key Dates

Keywords

Vaxcyte, PCVX, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Beneficial Ownership, Director, SEC Filing, Equity Securities